Publication details
Multimorbidita - závažný problém v přístupu k terapii diabetiků vyššího věku
| Title in English | Multimorbidity - a serious problem in the approach to the treatment of diabetic elderly |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | There is a lack of documents to a specific treatment polymorbid seniors because they are usually excluded from major clinical trials (RCTs = randomized clinical trials). The retrospective analysis of five general medical journals with the highest IF - RCT of 284 years from 1995 to 2010 were excluded, 65% of seniors for multiple morbidity. When evaluating 11 Cochrane Review MDG 4 by the presence of typical chronic diseases (diabetes, heart failure, COPD, stroke) was less than half of the participants in these studies meet the entry criteria of any of the following chronic diagnoses. Polymorbid seniors usually does not feature in the MDGs. Clinical guidelines generally do not count at all with multiple morbidity and often do not provide recommendations that take into account other simultaneously occurring comorbidities. Polyfarmacotherapy often justified and purposeful usually in old age depends primarily on co-existing polymorbidity. Although the individual diseases are quite rightly indicated and treated according to the EBM (evidence-based medicine), of which more than once threatened possible pharmacological interactions recede somewhat into the background. So it can be severe and difficult to detect. Principles of prescription seniors at a superficial glance may seem to give the impression that the prescription is similar in younger individuals. For seniors requires an understanding: a clear indication of the drug; knowledge of dosing; potential side reactions (NUL), and drug interactions. When geriatric prescription is necessary to take into account changes in cognitive function, decreased manual dexterity and vice versa rise to the need for social |